Dosing schedule for a novel anticancer agent

The invention is directed to methods for treating over-expression of the erbB2 in a mammal in need of treatment by administering to the mammal a therapeutically effective amount of a first inhibitor of an erbB2 receptor and then, after an interval of less than 24 hours, administering to the mammal f...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	NOE, DENNIS ALAN, CONNELL, RICHARD DAMIAN, STEYN, STEFANUS JOHANNES, BHATTACHARYA, SAMIT KUMAR, MOYER, JAMES DALE, JANI, JITESH PRANLAL
Format:	Patent
Sprache:	chi ; eng
Schlagworte:	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The invention is directed to methods for treating over-expression of the erbB2 in a mammal in need of treatment by administering to the mammal a therapeutically effective amount of a first inhibitor of an erbB2 receptor and then, after an interval of less than 24 hours, administering to the mammal from one to six therapeutically effective amounts of the same or different inhibitor of the erbB2 receptor. The invention is also directed to a slow daily infusion of the erbB2 inhibitor. The over-expression of the erbB2 receptor may result in abnormal cell growth and lead to cancer. By the methods of the invention, the efficacy and safety of the inhibitors is enhanced. The invention is also directed to kits for facilitating the dose administration method of the invention.